Status of Uric Acid Management in Hypertensive Subjects

Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists;...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hypertension research 2007-06, Vol.30 (6), p.549-554
Hauptverfasser: Yamamoto, Yasutaka, Matsubara, Koichi, Igawa, Go, Kaetsu, Yasuhiro, Sugihara, Shinobu, Matsuura, Takashi, Ando, Fumihiro, Sonoyama, Kazuhiko, Hamada, Toshihiro, Ogino, Kazuhide, Igawa, Osamu, Shigemasa, Chiaki, Hisatome, Ichiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 554
container_issue 6
container_start_page 549
container_title Hypertension research
container_volume 30
creator Yamamoto, Yasutaka
Matsubara, Koichi
Igawa, Go
Kaetsu, Yasuhiro
Sugihara, Shinobu
Matsuura, Takashi
Ando, Fumihiro
Sonoyama, Kazuhiko
Hamada, Toshihiro
Ogino, Kazuhide
Igawa, Osamu
Shigemasa, Chiaki
Hisatome, Ichiro
description Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and β-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed β-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.
doi_str_mv 10.1291/hypres.30.549
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68107671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68107671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-ddf39118d2ce2df2e752191b7ebce339f6d57660df8c71e5b07f3439af783a53</originalsourceid><addsrcrecordid>eNqFkEFLwzAUgIMobk6PXqUnb515Sds0xzHUCYqHzXNo05etY01r0gr790Y69OgpD_Lx8d5HyC3QOTAJD7tj59DPOZ2niTwjU-BJHicMknMypRKyWGY8m5Ar7_eUsjyVcEkmILIsCfOUiHVf9IOPWhN9uFpHC11X0Vthiy02aPuottHq2KHr0fr6C6P1UO5R9_6aXJji4PHm9M7I5ulxs1zFr-_PL8vFa6xTgD6uKsMlQF4xjawyDEXKQEIpsNTIuTRZlYZdaGVyLQDTkgrDEy4LI3JepHxG7kdt59rPAX2vmtprPBwKi-3gVZYDFZmAAMYjqF3rvUOjOlc3hTsqoOonlBpDKU5VCBX4u5N4KBus_uhTmQDMR8CHL7tFp_bt4Gy49T-jDUEd_hp3jlEqBOPfZ0B_Cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68107671</pqid></control><display><type>article</type><title>Status of Uric Acid Management in Hypertensive Subjects</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yamamoto, Yasutaka ; Matsubara, Koichi ; Igawa, Go ; Kaetsu, Yasuhiro ; Sugihara, Shinobu ; Matsuura, Takashi ; Ando, Fumihiro ; Sonoyama, Kazuhiko ; Hamada, Toshihiro ; Ogino, Kazuhide ; Igawa, Osamu ; Shigemasa, Chiaki ; Hisatome, Ichiro</creator><creatorcontrib>Yamamoto, Yasutaka ; Matsubara, Koichi ; Igawa, Go ; Kaetsu, Yasuhiro ; Sugihara, Shinobu ; Matsuura, Takashi ; Ando, Fumihiro ; Sonoyama, Kazuhiko ; Hamada, Toshihiro ; Ogino, Kazuhide ; Igawa, Osamu ; Shigemasa, Chiaki ; Hisatome, Ichiro</creatorcontrib><description>Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and β-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed β-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.</description><identifier>ISSN: 0916-9636</identifier><identifier>EISSN: 1348-4214</identifier><identifier>DOI: 10.1291/hypres.30.549</identifier><identifier>PMID: 17664859</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[Aged ; Aged, 80 and over ; Cardiology - statistics & numerical data ; Cross-Sectional Studies ; Enzyme Inhibitors - therapeutic use ; Female ; Geriatrics/Gerontology ; Health Promotion and Disease Prevention ; Humans ; Hypertension - blood ; Hyperuricemia - diagnosis ; Hyperuricemia - drug therapy ; Hyperuricemia - epidemiology ; Institutional Practice - statistics & numerical data ; Internal Medicine ; Japan - epidemiology ; Male ; Medicine ; Medicine & Public Health ; Obstetrics/Perinatology/Midwifery ; original-article ; Practice Patterns, Physicians' - statistics & numerical data ; Private Practice - statistics & numerical data ; Public Health ; Uric Acid - blood ; Uricosuric Agents - therapeutic use ; Xanthine Oxidase - antagonists & inhibitors]]></subject><ispartof>Hypertension research, 2007-06, Vol.30 (6), p.549-554</ispartof><rights>The Japanese Society of Hypertension 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-ddf39118d2ce2df2e752191b7ebce339f6d57660df8c71e5b07f3439af783a53</citedby><cites>FETCH-LOGICAL-c511t-ddf39118d2ce2df2e752191b7ebce339f6d57660df8c71e5b07f3439af783a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17664859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamamoto, Yasutaka</creatorcontrib><creatorcontrib>Matsubara, Koichi</creatorcontrib><creatorcontrib>Igawa, Go</creatorcontrib><creatorcontrib>Kaetsu, Yasuhiro</creatorcontrib><creatorcontrib>Sugihara, Shinobu</creatorcontrib><creatorcontrib>Matsuura, Takashi</creatorcontrib><creatorcontrib>Ando, Fumihiro</creatorcontrib><creatorcontrib>Sonoyama, Kazuhiko</creatorcontrib><creatorcontrib>Hamada, Toshihiro</creatorcontrib><creatorcontrib>Ogino, Kazuhide</creatorcontrib><creatorcontrib>Igawa, Osamu</creatorcontrib><creatorcontrib>Shigemasa, Chiaki</creatorcontrib><creatorcontrib>Hisatome, Ichiro</creatorcontrib><title>Status of Uric Acid Management in Hypertensive Subjects</title><title>Hypertension research</title><addtitle>Hypertens Res</addtitle><addtitle>Hypertens Res</addtitle><description>Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and β-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed β-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiology - statistics &amp; numerical data</subject><subject>Cross-Sectional Studies</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Geriatrics/Gerontology</subject><subject>Health Promotion and Disease Prevention</subject><subject>Humans</subject><subject>Hypertension - blood</subject><subject>Hyperuricemia - diagnosis</subject><subject>Hyperuricemia - drug therapy</subject><subject>Hyperuricemia - epidemiology</subject><subject>Institutional Practice - statistics &amp; numerical data</subject><subject>Internal Medicine</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>original-article</subject><subject>Practice Patterns, Physicians' - statistics &amp; numerical data</subject><subject>Private Practice - statistics &amp; numerical data</subject><subject>Public Health</subject><subject>Uric Acid - blood</subject><subject>Uricosuric Agents - therapeutic use</subject><subject>Xanthine Oxidase - antagonists &amp; inhibitors</subject><issn>0916-9636</issn><issn>1348-4214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFLwzAUgIMobk6PXqUnb515Sds0xzHUCYqHzXNo05etY01r0gr790Y69OgpD_Lx8d5HyC3QOTAJD7tj59DPOZ2niTwjU-BJHicMknMypRKyWGY8m5Ar7_eUsjyVcEkmILIsCfOUiHVf9IOPWhN9uFpHC11X0Vthiy02aPuottHq2KHr0fr6C6P1UO5R9_6aXJji4PHm9M7I5ulxs1zFr-_PL8vFa6xTgD6uKsMlQF4xjawyDEXKQEIpsNTIuTRZlYZdaGVyLQDTkgrDEy4LI3JepHxG7kdt59rPAX2vmtprPBwKi-3gVZYDFZmAAMYjqF3rvUOjOlc3hTsqoOonlBpDKU5VCBX4u5N4KBus_uhTmQDMR8CHL7tFp_bt4Gy49T-jDUEd_hp3jlEqBOPfZ0B_Cg</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Yamamoto, Yasutaka</creator><creator>Matsubara, Koichi</creator><creator>Igawa, Go</creator><creator>Kaetsu, Yasuhiro</creator><creator>Sugihara, Shinobu</creator><creator>Matsuura, Takashi</creator><creator>Ando, Fumihiro</creator><creator>Sonoyama, Kazuhiko</creator><creator>Hamada, Toshihiro</creator><creator>Ogino, Kazuhide</creator><creator>Igawa, Osamu</creator><creator>Shigemasa, Chiaki</creator><creator>Hisatome, Ichiro</creator><general>Nature Publishing Group UK</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Status of Uric Acid Management in Hypertensive Subjects</title><author>Yamamoto, Yasutaka ; Matsubara, Koichi ; Igawa, Go ; Kaetsu, Yasuhiro ; Sugihara, Shinobu ; Matsuura, Takashi ; Ando, Fumihiro ; Sonoyama, Kazuhiko ; Hamada, Toshihiro ; Ogino, Kazuhide ; Igawa, Osamu ; Shigemasa, Chiaki ; Hisatome, Ichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-ddf39118d2ce2df2e752191b7ebce339f6d57660df8c71e5b07f3439af783a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiology - statistics &amp; numerical data</topic><topic>Cross-Sectional Studies</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Geriatrics/Gerontology</topic><topic>Health Promotion and Disease Prevention</topic><topic>Humans</topic><topic>Hypertension - blood</topic><topic>Hyperuricemia - diagnosis</topic><topic>Hyperuricemia - drug therapy</topic><topic>Hyperuricemia - epidemiology</topic><topic>Institutional Practice - statistics &amp; numerical data</topic><topic>Internal Medicine</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>original-article</topic><topic>Practice Patterns, Physicians' - statistics &amp; numerical data</topic><topic>Private Practice - statistics &amp; numerical data</topic><topic>Public Health</topic><topic>Uric Acid - blood</topic><topic>Uricosuric Agents - therapeutic use</topic><topic>Xanthine Oxidase - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamamoto, Yasutaka</creatorcontrib><creatorcontrib>Matsubara, Koichi</creatorcontrib><creatorcontrib>Igawa, Go</creatorcontrib><creatorcontrib>Kaetsu, Yasuhiro</creatorcontrib><creatorcontrib>Sugihara, Shinobu</creatorcontrib><creatorcontrib>Matsuura, Takashi</creatorcontrib><creatorcontrib>Ando, Fumihiro</creatorcontrib><creatorcontrib>Sonoyama, Kazuhiko</creatorcontrib><creatorcontrib>Hamada, Toshihiro</creatorcontrib><creatorcontrib>Ogino, Kazuhide</creatorcontrib><creatorcontrib>Igawa, Osamu</creatorcontrib><creatorcontrib>Shigemasa, Chiaki</creatorcontrib><creatorcontrib>Hisatome, Ichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamamoto, Yasutaka</au><au>Matsubara, Koichi</au><au>Igawa, Go</au><au>Kaetsu, Yasuhiro</au><au>Sugihara, Shinobu</au><au>Matsuura, Takashi</au><au>Ando, Fumihiro</au><au>Sonoyama, Kazuhiko</au><au>Hamada, Toshihiro</au><au>Ogino, Kazuhide</au><au>Igawa, Osamu</au><au>Shigemasa, Chiaki</au><au>Hisatome, Ichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Status of Uric Acid Management in Hypertensive Subjects</atitle><jtitle>Hypertension research</jtitle><stitle>Hypertens Res</stitle><addtitle>Hypertens Res</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>30</volume><issue>6</issue><spage>549</spage><epage>554</epage><pages>549-554</pages><issn>0916-9636</issn><eissn>1348-4214</eissn><abstract>Hyperuricemia in hypertensive subjects has been considered one of risk factors of cardiovascular diseases. We investigated the status of uric acid management in 799 hypertensive subjects (432 females and 367 males; mean age 70.9 years) managed by 43 doctors (19 cardiologists and 24 noncardiologists; 25 private practice doctors and 18 hospital doctors). The serum uric acid level was available in 85.7% of the patients. This availability was equivalent regardless of facility size, and more cardiologists than noncardiologists monitored this information. The prevalence of hyperuricemia was 17.5% and was higher in men and in patients with high triglyceridemia, left ventricular hypertrophy, renal dysfunction, proteinuria, and smokers, but was not higher in subjects with chronic heart failure, diabetes mellitus, and those with prescriptions for diuretics and β-blockers. The average serum uric acid level was higher in men and patients with chronic heart failure, renal dysfunction, high triglyceridemia, low high-density cholesterolemia, smokers, and subjects prescribed β-blockers. Fifty percent of hyperuricemic patients were medicated, and 48.6% of them cleared the uric acid target level (6 mg/dL). No differences were observed in the treatment rate or the achievement rate of the target between genders, concurrent diseases, and physician specialties. Although doctors, especially cardiologists, have a high concern for the serum uric acid level, they do not intervene intensively, and specific treatment for individual patterns is not routinely given. Thus, more attention to uric acid management is necessary in hypertensive subjects to prevent cardiovascular diseases.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>17664859</pmid><doi>10.1291/hypres.30.549</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0916-9636
ispartof Hypertension research, 2007-06, Vol.30 (6), p.549-554
issn 0916-9636
1348-4214
language eng
recordid cdi_proquest_miscellaneous_68107671
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Aged
Aged, 80 and over
Cardiology - statistics & numerical data
Cross-Sectional Studies
Enzyme Inhibitors - therapeutic use
Female
Geriatrics/Gerontology
Health Promotion and Disease Prevention
Humans
Hypertension - blood
Hyperuricemia - diagnosis
Hyperuricemia - drug therapy
Hyperuricemia - epidemiology
Institutional Practice - statistics & numerical data
Internal Medicine
Japan - epidemiology
Male
Medicine
Medicine & Public Health
Obstetrics/Perinatology/Midwifery
original-article
Practice Patterns, Physicians' - statistics & numerical data
Private Practice - statistics & numerical data
Public Health
Uric Acid - blood
Uricosuric Agents - therapeutic use
Xanthine Oxidase - antagonists & inhibitors
title Status of Uric Acid Management in Hypertensive Subjects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A38%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Status%20of%20Uric%20Acid%20Management%20in%20Hypertensive%20Subjects&rft.jtitle=Hypertension%20research&rft.au=Yamamoto,%20Yasutaka&rft.date=2007-06-01&rft.volume=30&rft.issue=6&rft.spage=549&rft.epage=554&rft.pages=549-554&rft.issn=0916-9636&rft.eissn=1348-4214&rft_id=info:doi/10.1291/hypres.30.549&rft_dat=%3Cproquest_cross%3E68107671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68107671&rft_id=info:pmid/17664859&rfr_iscdi=true